Belvedere Trading’s XBiotech XBIT Stock Holding History

Belvedere Trading’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-14,600	Closed	-$228K	–	359
2020 Q4	$228K	Buy	+14,600	New	+$269K	0.01%	133

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Belvedere Trading's XBIT Position: Q1 2021 in Review

Belvedere Trading sold out of XBiotech (XBIT) in Q1 2021, closing a stake of 6,983 shares — an estimated $109K sold.

Belvedere Trading first reported a position in XBIT in Q4 2020 and held it in 1 quarter. The position peaked at $109K in Q4 2020. 65 funds tracked by Wall St. Rank hold XBIT as of Q1 2021.

Belvedere Trading reported no remaining XBiotech position as of Q1 2021 after selling out during the quarter.
Belvedere Trading sold 6,983 XBiotech shares in Q1 2021, an estimated $109K.
Belvedere Trading first reported a position in XBiotech in Q4 2020 and held it in 1 quarter.
Belvedere Trading's XBiotech position peaked at $109K in Q4 2020.
65 funds tracked by Wall St. Rank held XBiotech as of Q1 2021.

Based on Belvedere Trading's 13F filing for Q1 2021, filed 27 Apr 2021.